What is the history of Chordoma?

Chordoma was first identified in the mid-19th century as a rare, slow-growing cancer arising from remnants of the notochord, the embryonic structure that develops into the spinal column. While historically considered nearly untreatable, advancements in high-dose radiation and specialized surgical techniques have significantly improved prognosis and quality of life for those living with Chordoma.

When was Chordoma first identified?

The medical history of Chordoma began in 1857 when the German pathologist Rudolf Virchow described a "gelatinous" tumor found in the sacral region during an autopsy. He initially termed it "ecchondrosis physaliphora," believing it to be a cartilaginous growth. It was not until 1894 that physician Alfred Klebs identified these tumors as originating from the notochord, leading to the coining of the term "chordoma" in 1904 by Henri Ribbert.

How has our understanding of Chordoma evolved?

For many years, Chordoma was often misdiagnosed as other types of bone or cartilage tumors due to its complex location in the skull base or spine. The 20th century brought a shift in understanding the embryological origin of these cells, which persist in the body as notochordal remnants. Modern genomics has revolutionized the field, particularly with the discovery of the T (Brachyury) gene, which is now recognized as a key diagnostic marker and a primary driver of Chordoma development.

What are the major milestones in treatment?

Historically, Chordoma was notoriously resistant to conventional radiation and chemotherapy. The landscape changed with the following breakthroughs:

• 1980s-90s: The introduction of proton beam therapy provided a way to deliver high-dose radiation to the tumor while sparing critical structures like the brainstem.


• 2000s: The recognition that the Brachyury protein is highly expressed in Chordoma cells opened doors for targeted molecular therapies.


• Surgical Innovation: Advances in endoscopic endonasal surgery have allowed surgeons to reach tumors in the skull base with much less invasiveness than traditional open approaches.

How has patient advocacy shaped the field?

The Chordoma community has become a powerful force in research. With 34 members currently sharing their experiences on DiseaseMaps.org, patients are increasingly driving the research agenda by funding rare disease studies and participating in international registries to better understand this condition, which affects approximately 1 in 1,000,000 people annually.

Next steps

• Consult with a neuro-oncologist or specialized spine surgeon at a center of excellence that treats a high volume of Chordoma cases.


• Join specialized patient support groups to connect with others who understand the unique challenges of this rare diagnosis.


• Participate in clinical trials or registry programs to contribute to the global understanding of the disease.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD) - Chordoma


• Orphanet - Rare disease information on Chordoma


• Chordoma Foundation - Clinical research and patient resources


• OMIM (Online Mendelian Inheritance in Man) - T-gene and Chordoma research